Amgen Balans Gezondheid
Financiële gezondheid criteriumcontroles 1/6
Amgen heeft een totaal eigen vermogen van $7.5B en een totale schuld van $60.4B, wat de schuld-eigenvermogensverhouding op 802.4% brengt. De totale activa en totale passiva bedragen respectievelijk $90.9B en $83.4B. De EBIT Amgen is $6.7B waardoor de rentedekking 2.1 is. Het heeft contanten en kortetermijnbeleggingen van $9.0B.
Belangrijke informatie
802.4%
Verhouding schuld/eigen vermogen
US$60.40b
Schuld
| Rente dekkingsratio | 2.1x |
| Contant | US$9.01b |
| Aandelen | US$7.53b |
| Totaal verplichtingen | US$83.36b |
| Totaal activa | US$90.88b |
Recente financiële gezondheidsupdates
Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26
Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Recent updates
Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $26.8B ) AMGN } overtreffen de korte termijn passiva ( $20.3B ).
Langlopende schulden: De kortetermijnactiva van AMGN ( $26.8B ) dekken de langetermijnschulden ( $63.0B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 682.7% ) AMGN wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van AMGN is de afgelopen 5 jaar gestegen van 272.6% naar 802.4%.
Schuldendekking: De schuld van AMGN wordt niet goed gedekt door de operationele kasstroom ( 12% ).
Rentedekking: De rentebetalingen van AMGN op haar schulden worden niet goed gedekt door EBIT ( 2.1 x dekking).